Abstract
6084 Background: Cancer patients (pts) are on many medications, both for malignancy and supportive therapies. The cost of oral medications are funded by either the pt, public, or private mechanisms. Low adherence rates are observed in oral treatments, and non-adherence is the primary cause of treatment failures. To our knowledge, cost-related adherence to oral therapy in the context of malignancy has not been studied extensively in the existing literature. We assessed the relationships between oral medication costs and adherence rates. Methods: This cohort study enrolled 453 pts at 3 outpatient heme/onc clinics in the Greater Toronto Area. A 7-item survey was designed to assess pt demographics, self-reported adherence to oral medication, type of drug coverage (private payer, public payer, self payer) and patients' perceived cost of oral drugs. Oral medications were recorded and actual monthly costs were calculated. Descriptive statistics were used to describe frequencies. Spearman Rank Order Correlations and Chi-Square Analyses were used to examine relationships between variables. Results: Of 453 pts, 50% had a private drug plan, 24% paid out of pocket, 44% had government funding and 4% reported their physician had arranged funding. 51% of pts had oral drug costs of ≥ $100/month. Self reported adherence to prescribed oral medications was 80%. As the cost of prescribed medications increased, so did self reported adherence (r=0.144, p=0.002). There was also a significant relationship between drug coverage and oral drug costs (c²=23.78, df=12, p=0.02). Pts paying out of pocket were significantly less likely than all other pts to have oral drug costs of ≥$500/month (11% vs 19%) Conclusions: As oral drug costs increase, so does likelihood of adhering to prescribed regimen. This implies that further pt education about the efficacy and importance of medications may help with adherence, regardless of cost. It is possible that pts are provided with more education regarding newer and more expensive agents than they are regarding older and cheaper agents, regardless of efficacy. Disparities observed in medication costs between those with private drug plans vs. those without suggests financial restrictions may affect prescription patterns in this group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have